RxDoctor Payments Data

Stephanie Fischer

Family · South Bend, INNPI 1215665716

Payments from drug & device makers

$913in general payments, 2019–2025

Across 50 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$255
  • Medtronic$138
  • Kiniksa Pharmaceuticals International, PLC$71
  • Amgen$64
  • Pfizer$60
  • Boehringer Ingelheim$52
  • plus $273 from 10 others

What the payments were for

  • Food & beverage$913100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$913 in reported general payments places this provider in the 65th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$51,564
Medicare patients
440
Services billed
770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$190,667
EntrestoSacubitril/Valsartan58$58,564
XareltoRivaroxaban30$39,782
BrilintaTicagrelor40$22,923
Repatha SureclickEvolocumab17$15,741
JardianceEmpagliflozin12$10,539
FarxigaDapagliflozin Propanediol14$9,032
Dofetilide21$2,172
Metoprolol Succinate235$1,965
Atorvastatin Calcium253$1,898
Flecainide Acetate28$1,266
Ezetimibe45$1,092
Ranolazine ErRanolazine16$1,028
Digoxin18$1,015
Metoprolol Tartrate159$1,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$190,667198 claims
NovartisEntresto$255$58,56458 claims
Johnson & JohnsonXarelto$13$39,78230 claims
AstraZenecaBrilinta, Farxiga$30$31,95554 claims
Boehringer IngelheimJardiance$52$10,53912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,392 family providers in Indiana.

Other family in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →